review article | Q7318358 |
scholarly article | Q13442814 |
P2093 | author name string | David G Parkes | |
Kenneth F Mace | |||
Michael E Trautmann | |||
P2860 | cites work | A role for glucagon-like peptide-1 in the central regulation of feeding | Q24314317 |
Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor | Q24318252 | ||
Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1 | Q24563957 | ||
Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice | Q24629441 | ||
Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction | Q58447894 | ||
The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity | Q58448710 | ||
Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men | Q58448899 | ||
Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects | Q58449089 | ||
Exendin-4 and exendin-(9–39)NH2: agonist and antagonist, respectively, at the rat parietal cell receptor for glucagon-like peptide-1-(7–36)NH2 | Q58449146 | ||
Standards of medical care in diabetes--2012 | Q24632533 | ||
Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review | Q27023364 | ||
Structure-function of the glucagon receptor family of G protein-coupled receptors: the glucagon, GIP, GLP-1, and GLP-2 receptors | Q28203273 | ||
Exendin-4 ameliorates motor neuron degeneration in cellular and animal models of amyotrophic lateral sclerosis | Q28481242 | ||
Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis | Q28570314 | ||
Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats | Q28578709 | ||
Relationships of upper gastrointestinal motor and sensory function with glycemic control | Q32050159 | ||
Bioactive peptides from lizard venoms | Q34062907 | ||
Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis | Q34237350 | ||
Association of pancreatitis with glucagon-like peptide-1 agonist use. | Q34618507 | ||
Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies | Q34627077 | ||
Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). | Q34986024 | ||
Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual beta-cell function | Q35060123 | ||
Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes | Q35618856 | ||
Importance of quantifying insulin secretion in relation to insulin sensitivity to accurately assess beta cell function in clinical studies | Q35649213 | ||
Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy | Q35748345 | ||
Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus | Q35824086 | ||
Target-mediated pharmacokinetic and pharmacodynamic model of exendin-4 in rats, monkeys, and humans | Q35913076 | ||
Physiology of GLP-1--lessons from glucoincretin receptor knockout mice | Q36012473 | ||
Effect of renal impairment on the pharmacokinetics of exenatide | Q36024667 | ||
Therapeutic approaches to preserve islet mass in type 2 diabetes | Q36366851 | ||
Relative risk of acute pancreatitis in initiators of exenatide twice daily compared with other anti-diabetic medication: a follow-up study | Q36420499 | ||
Fatty liver: a novel component of the metabolic syndrome | Q36906553 | ||
GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism | Q37078997 | ||
Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus | Q37141727 | ||
The incretin system and its role in type 2 diabetes mellitus | Q37266863 | ||
Glucagon-like peptide-1 can reverse the age-related decline in glucose tolerance in rats | Q37368678 | ||
Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans | Q37377728 | ||
Role of the incretin pathway in the pathogenesis of type 2 diabetes mellitus | Q37642377 | ||
Glucagon-like peptide 1 receptor stimulation as a means of neuroprotection | Q37686556 | ||
A cohort study of acute pancreatitis in relation to exenatide use. | Q37841739 | ||
Encapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes | Q37900626 | ||
The effects of exenatide bid on metabolic control, medication use and hospitalization in patients with type 2 diabetes mellitus in clinical practice: a systematic review | Q37954675 | ||
Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta). | Q38324621 | ||
Exenatide does not evoke pancreatitis and attenuates chemically induced pancreatitis in normal and diabetic rodents | Q38340339 | ||
The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice | Q38363214 | ||
Exenatide reduces final infarct size in patients with ST-segment-elevation myocardial infarction and short-duration of ischemia | Q38473330 | ||
Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. | Q39778606 | ||
A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells | Q40748616 | ||
Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure | Q41267217 | ||
Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways | Q42165735 | ||
Regulation of glucose transporters and hexose uptake in 3T3-L1 adipocytes: glucagon-like peptide-1 and insulin interactions | Q42450579 | ||
Identification of glucagon-like peptide 1 (GLP-1) actions essential for glucose homeostasis in mice with disruption of GLP-1 receptor signaling | Q42454515 | ||
Altered cAMP and Ca2+ signaling in mouse pancreatic islets with glucagon-like peptide-1 receptor null phenotype | Q42478360 | ||
Glucagon-like peptide-1(7-36) amide (GLP-1) enhances insulin-stimulated glucose metabolism in 3T3-L1 adipocytes: one of several potential extrapancreatic sites of GLP-1 action. | Q42492827 | ||
Glucagon-like peptide-1 and exendin-4 stimulate beta-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age. | Q42506332 | ||
Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the beta-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4. | Q42520650 | ||
Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4. | Q42524942 | ||
The exenatide analogue AC3174 attenuates hypertension, insulin resistance, and renal dysfunction in Dahl salt-sensitive rats | Q42533774 | ||
Exenatide is non-inferior to insulin in reducing HbA1c: an integrated analysis of 1423 patients with type 2 diabetes | Q42660412 | ||
Glucagon-like peptide-1 receptor activation modulates pancreatitis-associated gene expression but does not modify the susceptibility to experimental pancreatitis in mice | Q43064614 | ||
The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice | Q43231241 | ||
Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas | Q43276184 | ||
Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury | Q43574002 | ||
Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro | Q43586628 | ||
Glucose competence of the hepatoportal vein sensor requires the presence of an activated glucagon-like peptide-1 receptor | Q43687822 | ||
The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes | Q43913927 | ||
Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice | Q44145661 | ||
Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. | Q44193794 | ||
Role of endogenous glucagon-like peptide-1 in islet regeneration after partial pancreatectomy | Q44286369 | ||
Neonatal exendin-4 prevents the development of diabetes in the intrauterine growth retarded rat. | Q44328972 | ||
Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes | Q44620317 | ||
Ex vivo human placental transfer of the peptides pramlintide and exenatide (synthetic exendin-4). | Q44781512 | ||
Exendin-4 normalized postcibal glycemic excursions in type 1 diabetes | Q44968815 | ||
Exenatide (exendin-4) improves insulin sensitivity and {beta}-cell mass in insulin-resistant obese fa/fa Zucker rats independent of glycemia and body weight | Q45200771 | ||
Exenatide improves hypertension in a rat model of the metabolic syndrome | Q46042040 | ||
Exendin-4 has an anti-hypertensive effect in salt-sensitive mice model | Q46159268 | ||
Dose-response for glycaemic and metabolic changes 28 days after single injection of long-acting release exenatide in diabetic fatty Zucker rats | Q46509023 | ||
Pharmacokinetics and pharmacodynamics of exenatide following alternate routes of administration | Q46740431 | ||
Antiobesity action of peripheral exenatide (exendin-4) in rodents: effects on food intake, body weight, metabolic status and side-effect measures | Q46988910 | ||
Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas | Q47234077 | ||
Peripheral versus central effects of glucagon-like peptide-1 receptor agonists on satiety and body weight loss in Zucker obese rats | Q47235596 | ||
Enhanced glucose-dependent insulinotropic polypeptide secretion and insulinotropic action in glucagon-like peptide 1 receptor -/- mice | Q47904088 | ||
The glucagon-like peptide 1 (GLP-1) analogue, exendin-4, decreases the rewarding value of food: a new role for mesolimbic GLP-1 receptors. | Q47996706 | ||
Exendin-4, but not glucagon-like peptide-1, is cleared exclusively by glomerular filtration in anaesthetised pigs | Q48725317 | ||
Mouse pancreatic beta-cells exhibit preserved glucose competence after disruption of the glucagon-like peptide-1 receptor gene | Q50892144 | ||
The effects of 13 wk of liraglutide treatment on endocrine and exocrine pancreas in male and female ZDF rats: a quantitative and qualitative analysis revealing no evidence of drug-induced pancreatitis. | Q51339510 | ||
Effects of intravenous exenatide in type 2 diabetic patients with congestive heart failure: a double-blind, randomised controlled clinical trial of efficacy and safety. | Q51368060 | ||
Liraglutide as additional treatment for type 1 diabetes. | Q51372390 | ||
Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM. | Q51578359 | ||
Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients. | Q51581246 | ||
Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. | Q51601217 | ||
Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. | Q52522147 | ||
Exenatide alters myocardial glucose transport and uptake depending on insulin resistance and increases myocardial blood flow in patients with type 2 diabetes. | Q53163778 | ||
Investigation of exenatide elimination and its in vivo and in vitro degradation. | Q53621094 | ||
P433 | issue | 2 | |
P407 | language of work or name | English | Q1860 |
P304 | page(s) | 219-244 | |
P577 | publication date | 2012-12-12 | |
P1433 | published in | Expert Opinion on Drug Discovery | Q5421204 |
P1476 | title | Discovery and development of exenatide: the first antidiabetic agent to leverage the multiple benefits of the incretin hormone, GLP-1. | |
P478 | volume | 8 |
Q41968812 | A Modular Method for the High-Yield Synthesis of Site-Specific Protein-Polymer Therapeutics |
Q34139490 | Advances in targeting cyclic nucleotide phosphodiesterases |
Q38610892 | Anti-diabetic actions of esculentin-2CHa(1-30) and its stable analogues in a diet-induced model of obesity-diabetes. |
Q26829445 | Assessment of pancreatic β-cell function: review of methods and clinical applications |
Q36930354 | Autophagy deficiency in β cells blunts incretin-induced suppression of glucagon release from α cells |
Q38311702 | Beyond traditional pharmacology: new tools and approaches |
Q28083144 | Clinical utility and patient considerations in the use of the sitagliptin-metformin combination in Chinese patients |
Q38311095 | Combined antidiabetic benefits of exenatide and dapagliflozin in diabetic mice |
Q91813042 | Comparison of ELISA and HPLC-MS methods for the determination of exenatide in biological and biotechnology-based formulation matrices |
Q90679732 | Drug Repurposing in Parkinson's Disease |
Q36006629 | Effects of E2HSA, a Long-Acting Glucagon Like Peptide-1 Receptor Agonist, on Glycemic Control and Beta Cell Function in Spontaneous Diabetic db/db Mice |
Q36067255 | Evasins: Therapeutic Potential of a New Family of Chemokine-Binding Proteins from Ticks |
Q52685416 | Exenatide once weekly for smoking cessation: study protocol for a randomized clinical trial. |
Q38179267 | Exenatide twice daily: a review of its use in the management of patients with type 2 diabetes mellitus |
Q33734024 | GLP-1(28-36)amide, the Glucagon-like peptide-1 metabolite: friend, foe, or pharmacological folly? |
Q36801780 | Herbal therapies for type 2 diabetes mellitus: chemistry, biology, and potential application of selected plants and compounds |
Q37193295 | Incretin action in the pancreas: potential promise, possible perils, and pathological pitfalls |
Q46099197 | Long-term metabolic benefits of exenatide in mice are mediated solely via the known glucagon-like peptide 1 receptor |
Q35594860 | Overcoming Insulin Insufficiency by Forced Follistatin Expression in β-cells of db/db Mice |
Q34458897 | Specialized insulin is used for chemical warfare by fish-hunting cone snails. |
Q21129358 | The central GLP-1: implications for food and drug reward |
Q26768527 | The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action |
Q38275171 | The ongoing pursuit of neuroprotective therapies in Parkinson disease |
Q51300453 | [I10W]tigerinin-1R enhances both insulin sensitivity and pancreatic beta cell function and decreases adiposity and plasma triglycerides in high-fat mice. |